Good
Partially Aligned
Patient Risk:
Low
Summary
Most provided claims (indication, mechanism description, exercise capacity/disease progression framing, and listed common adverse reactions) are supported by the provided prescribing information excerpts. However, the manufacturer claim is not covered by the supplied label text, and the mechanism/exercise capacity/progression phrasing is not explicitly stated in the excerpts beyond general effect on progression/hospitalization and mechanism as an IP receptor agonist.
Category Scores
Accurate Statements
Uptravi, also known as selexipag, is used to treat pulmonary arterial hypertension (PAH) in adults.
Indications and Usage: UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Common side effects associated with Uptravi include headache.
Adverse Reactions (Table 3): Headache 65% vs 32%.
Common side effects associated with Uptravi include diarrhea.
Adverse Reactions (Table 3): Diarrhea 42% vs 18%.
Common side effects associated with Uptravi include jaw pain.
Adverse Reactions (Table 3): Jaw pain 26% vs 6%.
Common side effects associated with Uptravi include nausea.
Adverse Reactions (Table 3): Nausea 33% vs 18%.
Common side effects associated with Uptravi include vomiting.
Adverse Reactions (Table 3): Vomiting 18% vs 9%.
Unsupported Statements
Uptravi is manufactured by Actelion Pharmaceuticals.
No manufacturer attribution is provided in the supplied prescribing information excerpts.
Uptravi works by relaxing blood vessels.
The provided label excerpt describes selexipag as a prostacyclin receptor/IP receptor agonist (mechanism). It does not explicitly state 'relaxing blood vessels.'
Uptravi can help improve exercise capacity.
The provided excerpts discuss delaying disease progression and reducing hospitalization risk, but do not mention exercise capacity.
Uptravi can help reduce the risk of disease progression.
The excerpt supports delaying disease progression and reducing risk of hospitalization; however, 'reduce the risk of disease progression' is not stated verbatim in the provided text for this exact phrasing.
Common side effects associated with Uptravi include pain in extremity.
The provided adverse-reaction excerpt lists headache, diarrhea, jaw pain, nausea, vomiting, and other items, but does not include 'pain in extremity' specifically.
Common side effects associated with Uptravi include flushing.
The provided adverse-reaction excerpt does not list 'flushing' specifically.
Contradictions
Important Omissions
No claim addressed contraindications, boxed warnings, warnings/precautions, dosing details, monitoring, or drug interactions; therefore safety-relevant label content is not evaluated against any specific user claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated largely concern indication and common adverse reactions; the only safety-relevant potential mismatch is that a couple of adverse reactions ('pain in extremity', 'flushing') and efficacy ('exercise capacity') are not explicitly supported by the provided excerpts, which could lead to inaccurate expectation-setting. No contraindication or warning conflicts were identified.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (manufacturer, 'relaxing blood vessels' wording, 'exercise capacity', and specific adverse reactions 'pain in extremity' and 'flushing').
Suggested Improvement
Rephrase mechanism to match the label excerpt (IP receptor/prostacyclin receptor agonist) and limit efficacy statements to 'delay disease progression' and 'reduce risk of hospitalization' as supported. Only list adverse reactions that are explicitly shown in the provided Table 3 excerpt.